// App-Quantinova.ai

930 : A half-life extended bispecific Humabody VH delivering dual checkpoint blockade to reverse the dysfunction of LAG3+PD-1+ double-positive T cells

Researchers

Presenter

  • James William Legg

Principal Investigators

  • Hugo Arasanz

  • Ana Bocanegra

  • Phillip Bartlett

  • Giovanni Benedetti

  • Neil Birkett

  • Carl Cox

  • Elena De Juan

  • Carrie Enever

  • Emma Hames

  • Grazyna Kochan

  • Maria Jesus Garcia-Granda

  • Angelica Sette

  • Yumin Teng

  • Lorraine Thompson

  • Ruth Vera

  • Richard Williams

  • Miren Zuazo

  • David Escors

  • Carolyn Edwards

Medical Centers

  • Crescendo Biologics Ltd, Cambridge, United Kingdom.

  • Complejo Hospitalario de Navarra and Fundacion Miguel Servet, Instituto de Investigaciones Sanitarias de Navarra (IdISNA), Pamplona, Spain

  • Navarrabiomed. Fundación Miguel Servet. Instituto de Investigaciones Sanitarias de Navarra (IdISNA) UPNA, Pamplona, Spain

Locations

  • United Kingdom

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • Interleukin-2

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved